For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
To read the full story
Related Article
BUSINESS
- AbbVie Taps Tiago Campos Rodrigues as Japan President
October 28, 2024
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Recordati to Enter Japan’s Hematology/Oncology Market with Enjaymo Acquisition
October 25, 2024
- Novo Inks Collab Pact with Kasugai City on Obesity Measures
October 25, 2024
- Shionogi-Ube’s Anti-RSV Drug Gets Fast-Track Tag in US
October 25, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…